This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

A few biotech stocks took a tumble Tuesday amid earnings, regulatory setbacks and a management shakeup.

In earnings, medical technology company Biolase Technology (BLTI) reported a net loss of $3.1 million, or 15 cents a share, vs. a loss of $1 million, or 4 cents a share, in the 2006 quarter. The company reported net revenue of $12.8 million, compared to $17.1 million in the year-ago period. Analysts surveyed by Thomson Financial had expected a loss of 2 cents a share on revenue of $18.3 million.

Additionally, the company said that CEO Jeffrey Jones is leaving the company immediately, and Federico Pignatelli, an independent director, will serve as interim CEO while a replacement is sought. Keith Bateman, executive vice president of global sales and marketing, also is leaving immediately and the company is searching for his replacement. Shares gave up $2.45, or 45%, to $2.97.

Also, Albany Molecular Research (AMRI - Get Report) missed on earnings Tuesday and fell $5.59, or 32%, to $11.82. The company reported adjusted earnings of $2 million, or 6 cents a share, vs. $1.4 million, or 4 cents a share in the year-earlier period. Revenue came in at $47.56 million, vs. $44.2 in the 2006 quarter. But analysts surveyed by Thomson Financial expected 9 cents a share on revenue of $48.3 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMRI $19.97 1.73%
ANIK $33.15 -1.46%
MNTA $21.09 -0.14%
SPPI $6.19 0.81%
TSLA $248.35 -0.44%

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs